Skip to main content
. 2018 Sep 9;8(17):4664–4678. doi: 10.7150/thno.26619

Figure 3.

Figure 3

ICL1-9 reduces fibrotic remodeling following I/R. Cardiac remodeling responses to Scr or ICL1-9 pepducin were assessed via gravimetric and immunohistological analyses 4 weeks post-I/R. (A) Quantification of gravimetric analysis of heart weight normalized to tibia length. n=8 Sham Scr, n=8 Sham ICL1-9, n=12 I/R Scr, n=11 I/R ICL1-9, ns = not significant, ** p < 0.01, one-way ANOVA with Tukey's multiple comparison test. (B) Representative wheat germ agglutinin (WGA) staining of hearts to assess cardiomyocyte cross sectional area. (C) Quantification of cardiomyocyte size from WGA-stained hearts. n=7 Scr Sham, n=8 ICL1-9 Sham, n=12 Scr I/R, n=11 ICL1-9 I/R, ns = not significant, * p < 0.05, one-way ANOVA with Tukey's multiple comparison test. (D) Representative Masson trichrome staining of Scr or ICL1-9 pepducin-injected hearts following I/R injury. (E) Quantification of fibrosis from Masson trichrome-stained hearts, expressed as a percentage of the total LV area. n=8 Sham Scr, n=8 Sham ICL1-9, n=10 I/R Scr, n=10 I/R ICL1-9, ns = not significant, ** p < 0.01, *** p < 0.001, one-way ANOVA with Tukey's multiple comparison test.